About Scribe Therapeutics
Scribe Therapeutics is a company based in Alameda (United States) founded in 2018 by Jennifer A Doudna, Brett T Staahl, and David F Savage.. Scribe Therapeutics has raised $120 million across 2 funding rounds from investors including T. Rowe Price, Orbimed and RA Capital. Scribe Therapeutics offers products and services including CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology. Scribe Therapeutics operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
- Headquarter Alameda, United States
- Founders Jennifer A Doudna, Brett T Staahl, David F Savage
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$120 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series B
Mar 17, 2021
-
Investors
T. Rowe Price
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scribe Therapeutics
Scribe Therapeutics offers a comprehensive portfolio of products and services, including CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineers CRISPR systems for safe treatment of genetic diseases.
Develops technology for long-term genetic regulation in disease management.
Unlock access to complete
Unlock access to complete
Funding Insights of Scribe Therapeutics
Scribe Therapeutics has successfully raised a total of $120M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $100.0M
-
First Round
First Round
(06 Oct 2020)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series B - Scribe Therapeutics | Valuation | Avoro Capital Advisors | |
| Oct, 2020 | Amount | Series A - Scribe Therapeutics | Valuation | a16z |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Scribe Therapeutics
Scribe Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, Orbimed and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on biotechnology startups
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Scribe Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Scribe Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scribe Therapeutics Comparisons
Competitors of Scribe Therapeutics
Scribe Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| domain | founded_year | HQ Location |
Genetic therapies for diseases are developed using prime editing technology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scribe Therapeutics
Frequently Asked Questions about Scribe Therapeutics
When was Scribe Therapeutics founded?
Scribe Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Scribe Therapeutics located?
Scribe Therapeutics is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Is Scribe Therapeutics a funded company?
Scribe Therapeutics is a funded company, having raised a total of $120M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Oct 06, 2020.
What does Scribe Therapeutics do?
Founded in 2018 and headquartered in Alameda, United States, Scribe Therapeutics operates in the biotechnology sector. A proprietary X-editing (XE) platform, utilizing CRISPR technology and CasX enzymes with guide RNAs, is employed for in vivo genome modifications. Targeted genetic diseases include neurological and ophthalmological conditions, hematopoietic disorders, and applications in cell therapy. The platform enables precise gene knock-in or knock-out to address these health challenges.
Who are the top competitors of Scribe Therapeutics?
Scribe Therapeutics's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
What products or services does Scribe Therapeutics offer?
Scribe Therapeutics offers CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology.
Who are Scribe Therapeutics's investors?
Scribe Therapeutics has 8 investors. Key investors include T. Rowe Price, Orbimed, RA Capital, Perceptive Advisors, and Avoro Capital Advisors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.